Article Text

Download PDFPDF
CP-163 Evaluation of effectiveness and safety of Rilpivirine/Emtricitabine/ Tenofovir
  1. A Andrés Rosado,
  2. A Ontañón Nasarre,
  3. A Carrasco Torrents,
  4. FJ Farfán Sedano
  1. Fuenlabrada University Hospital, Hospital Pharmacy, Madrid, Spain

Abstract

Background The combination rilpivirine (RPV)/emtricitabine (FTC)/tenofovir (TDF) has been approved for the treatment of patients with HIV infection with a viral load (VL) ≤100,000 copies/mL.

Purpose To evaluate the effectiveness and safety of RPV/TDF/FTC in treatment-naïve and pretreated patients with HIV infection in a second level hospital.

Material and methods Retrospective observational study (June 2013–September 2014). We included patients with HIV infection, treatment-naïve and pretreated, being treated with RPV/TDF/FTC. The effectiveness was measured by the virological and immunological response. Virological response was considered when VL was undetectable (VL <50 copies/mL) and immunological response when CD4 count was greater than 200 cells/mm3 after 6 months of treatment. VL and CD4 count were collected at baseline and 6 months later. Patients who had less than 3 months on treatment were excluded, because no analytical data are available to assess the effectiveness. Safety was evaluated through side effects (SE).

Results 15 patients were included, 3 treatment-naïve and 12 pretreated. 42% (5/12) of pretreated patients switched treatment to RPV/TDF/FTC due to SE, 25% (3/12) to simplify treatment, 25% (3/12) for psychiatric reasons and 8%(1/12) for poor adherence.

67% (8/12) of pretreated patients had an undetectable baseline VL, 8% (1/12) had VL 50–100 copies/mL and 25% (3/12) had VL > 100 copies/mL. Baseline CD4 count average was 377 cells/mm3 (79–655). Baseline VL average of treatment-naïve patients were 31,043 copies/mL (3,530–49,000) and baseline average CD4 count was 329 cells/mm3 (200–430).

After 6 months, treatment were effective in 75% (9/12) of pretreated and 67% (2/3) of treatment-naïve patients.

13% (2/15) reported SE. 1 patient reported insomnia and another patient insomnia, fatigue, gastrointestinal disorders and dyspnoea due to which he left treatment.

Conclusion RPV/TDF/FTC has been shown to be effective in treatment of HIV infection, in treatment-naïve (67%) and in pretreated patients (75%). The SE profile is low, however one patient had to leave treatment for this reason.

References and/or Acknowledgements No conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.